CN101222925A - 嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品 - Google Patents

嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品 Download PDF

Info

Publication number
CN101222925A
CN101222925A CNA2006800263848A CN200680026384A CN101222925A CN 101222925 A CN101222925 A CN 101222925A CN A2006800263848 A CNA2006800263848 A CN A2006800263848A CN 200680026384 A CN200680026384 A CN 200680026384A CN 101222925 A CN101222925 A CN 101222925A
Authority
CN
China
Prior art keywords
combination product
acid
pharmaceutical combination
phenyl
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800263848A
Other languages
English (en)
Chinese (zh)
Inventor
P·W·曼雷
H·莱恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101222925A publication Critical patent/CN101222925A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2006800263848A 2005-07-20 2006-07-19 嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品 Pending CN101222925A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70110405P 2005-07-20 2005-07-20
US60/701,104 2005-07-20

Publications (1)

Publication Number Publication Date
CN101222925A true CN101222925A (zh) 2008-07-16

Family

ID=37517254

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800263848A Pending CN101222925A (zh) 2005-07-20 2006-07-19 嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品

Country Status (11)

Country Link
US (1) US20080200486A1 (enExample)
EP (2) EP1909794A2 (enExample)
JP (1) JP2009501765A (enExample)
KR (3) KR20080041206A (enExample)
CN (1) CN101222925A (enExample)
AU (1) AU2006271650B8 (enExample)
BR (1) BRPI0613692A2 (enExample)
CA (1) CA2615254C (enExample)
MX (1) MX2008000897A (enExample)
RU (1) RU2443418C2 (enExample)
WO (1) WO2007010012A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2538683C2 (ru) * 2008-10-31 2015-01-10 Новартис Аг КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (Р13К) И ИНГИБИТОРА mTOR
KR102432999B1 (ko) 2018-08-29 2022-08-17 고려대학교 산학협력단 마이크로파 조사를 이용한 체외 아밀로이드 응집체 합성방법
CN110613848A (zh) * 2019-10-29 2019-12-27 西安交通大学医学院第二附属医院 Tipe1作为靶点在制备防治银屑病的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
JP4105761B2 (ja) 1993-11-19 2008-06-25 アボット・ラボラトリーズ ラパミシン（マクロライド）の半合成類似体免疫調節剤
CZ284650B6 (cs) 1993-12-17 1999-01-13 Novartis Ag Nové demethoxyderiváty rapamycinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
KR100400620B1 (ko) 1995-06-09 2004-02-18 노파르티스 아게 라파마이신유도체
LT3351246T (lt) * 2001-02-19 2019-07-10 Novartis Pharma Ag Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003248813A1 (en) * 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
JP2009501765A (ja) 2009-01-22
CA2615254C (en) 2013-09-24
BRPI0613692A2 (pt) 2011-01-25
EP2253320A1 (en) 2010-11-24
AU2006271650B2 (en) 2011-01-06
MX2008000897A (es) 2008-03-18
WO2007010012A3 (en) 2007-07-05
KR20130087058A (ko) 2013-08-05
AU2006271650A1 (en) 2007-01-25
US20080200486A1 (en) 2008-08-21
WO2007010012A2 (en) 2007-01-25
RU2008105828A (ru) 2009-08-27
RU2443418C2 (ru) 2012-02-27
KR20120079163A (ko) 2012-07-11
AU2006271650B8 (en) 2011-02-10
EP1909794A2 (en) 2008-04-16
KR20080041206A (ko) 2008-05-09
CA2615254A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
TWI592157B (zh) 治療增生性疾病及其他由ｂｃｒ－ａｂｌ、ｃ－ｋｉｔ、ｄｄｒ１、ｄｄｒ２或ｐｄｇｆ－ｒ激酶活性所調節之病症之方法
CN101415426A (zh) c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途
US20110281902A1 (en) Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag
US20080255171A1 (en) Combination of Nilotinib with Farnesyl Transferase Inhibitors
EP2007391B1 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
CN101180060B (zh) 治疗或预防增殖性疾病的嘧啶基氨基苯甲酰胺化合物和伊马替尼的组合
RU2443418C2 (ru) КОМБИНАЦИЯ ПИРИМИДИЛАМИНОБЕНЗАМИДА И ИНГИБИТОРА КИНАЗ mTOR
WO2007051862A1 (en) Combination of organic compounds
US20080207658A1 (en) Pharmaceutical Combination of Bcr-Abl and Raf Inhibitors
AU2011202833B2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20080716